Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer

(2013) D. Park et al.   CANCER RESEARCH

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity

(2012) Virginie Monceau et al.   CURRENT DRUG TARGETS

An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737

(2011) S. Al-harbi et al.   BLOOD

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

(2011) K J Harrington et al.   BRITISH JOURNAL OF CANCER

Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties

(2011) N C Yip et al.   BRITISH JOURNAL OF CANCER

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

(2011) Ayesha B. Alvero et al.   CELL CYCLE

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents

(2011) Cyrille Touzeau et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer

(2011) Francesca De Bacco et al.   JNCI-Journal of the National Cancer Institute

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists

(2010) Brian J. Lestini et al.   CANCER BIOLOGY & THERAPY

Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression

(2010) Kristen E. Olberding et al.   CANCER BIOLOGY & THERAPY

The Canonical NF- B Pathway Governs Mammary Tumorigenesis in Transgenic Mice and Tumor Stem Cell Expansion

(2010) M. Liu et al.   CANCER RESEARCH

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma

(2010) Natini Jinawath et al.   PLoS One

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia

(2008) M. Vogler et al.   BLOOD

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer

(2008) C. L. Hann et al.   CANCER RESEARCH

Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737

(2008) K. Okumura et al.   CLINICAL CANCER RESEARCH

Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database

(2008) Brian E. Lally et al.   LUNG CANCER